APTO vs. INAB, SABS, CLDI, CRIS, ATHA, CHRO, BCDA, PMCB, TSBX, and OMGA
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include IN8bio (INAB), SAB Biotherapeutics (SABS), Calidi Biotherapeutics (CLDI), Curis (CRIS), Athira Pharma (ATHA), Chromocell Therapeutics (CHRO), BioCardia (BCDA), PharmaCyte Biotech (PMCB), Turnstone Biologics (TSBX), and Omega Therapeutics (OMGA). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences vs.
IN8bio (NASDAQ:INAB) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
IN8bio presently has a consensus target price of $6.00, indicating a potential upside of 3,510.11%. Aptose Biosciences has a consensus target price of $93.00, indicating a potential upside of 0.00%. Given IN8bio's higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Aptose Biosciences.
IN8bio's return on equity of -197.15% beat Aptose Biosciences' return on equity.
92.1% of IN8bio shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 15.5% of IN8bio shares are held by insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Aptose Biosciences received 358 more outperform votes than IN8bio when rated by MarketBeat users. However, 74.29% of users gave IN8bio an outperform vote while only 61.94% of users gave Aptose Biosciences an outperform vote.
IN8bio is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aptose Biosciences had 1 more articles in the media than IN8bio. MarketBeat recorded 1 mentions for Aptose Biosciences and 0 mentions for IN8bio. IN8bio's average media sentiment score of 1.00 beat Aptose Biosciences' score of 0.00 indicating that IN8bio is being referred to more favorably in the media.
IN8bio has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
Summary
IN8bio beats Aptose Biosciences on 10 of the 16 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:APTO) was last updated on 4/22/2025 by MarketBeat.com Staff
Buy APTO Stock Free APTO Stock Alerts